SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

With no major difference for the quarter endedDecember 2022 , the total revenue stood at Rs. 2519.48  millions.The Net Loss for the quarter ended December 2022 is Rs. -571.26 millions as compared to Net Loss of Rs. -235.00 millions of corresponding quarter ended December 2021 Operating profit Margin for the quarter ended December 2022 further decreased to -267.30% as compared to -18.07% of corresponding quarter ended December 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 2519.48 2482.91 1.47 7623.67 6660.61 14.46 9429.27 11239.73 -16.11
Other Income 154.33 150.89 2.28 380.58 329.90 15.36 420.68 473.71 -11.19
PBIDT -267.30 -18.07 1379.25 -461.22 -230.56 100.04 -14.87 1428.38 -101.04
Interest 17.61 3.29 435.26 64.49 14.97 330.79 20.74 13.01 59.42
PBDT -284.91 -21.36 1233.85 -575.93 -245.53 134.57 -35.61 1415.37 -102.52
Depreciation 286.35 213.64 34.03 776.62 619.20 25.42 831.88 758.92 9.61
PBT -571.26 -235.00 143.09 -1352.55 -864.73 56.41 -867.49 656.45 -232.15
TAX 0.00 0.00 0.00 206.12 -137.11 -250.33 -313.18 115.63 -370.85
Deferred Tax 0.00 0.00 0.00 206.12 -139.48 -247.78 -315.55 109.43 -388.36
PAT -571.26 -235.00 143.09 -1558.67 -727.62 114.21 -554.31 540.82 -202.49
Equity 140.81 140.81 0.00 140.81 140.81 0.00 140.81 140.81 0.00
PBIDTM(%) -10.61 -0.73 1357.72 -6.05 -3.46 74.77 -0.16 12.71 -101.24

Unichem Lab Share Price

347.75 2.75 (0.80%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×